FGF8 and hepatocellular carcinoma: Meanwhile, exogenous recombinant FGF8 plays a critical role in the resistance to EGFR inhibitor gefitinib in HCC cells, but not to other anticancer chemotherapeutic drugs, such as doxorubicin, 5-Fu, paclitaxel, RAD001, and oxaliplatin (Liu et al., 2015a).